Free Trial

This company recently went public with an IPO on Friday, October 30th 2026. They issued 9,375,000 shares at $15.00 - $17.00 per share. We will continue to update data for ASPE as it becomes available.

Aspen Neuroscience (ASPE) 10K Form and Latest SEC Filings 2026

$13.04 -1.85 (-12.42%)
As of 11/2/2026 04:00 PM Eastern

Latest Aspen Neuroscience SEC Filings & Recent Activity

Aspen Neuroscience (NASDAQ:ASPE) has submitted 26+ documents to the U.S. Securities and Exchange Commission (SEC) since 2026. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on November 2, 2026.

Form 4
Aspen Neuroscience, Inc. Reports Ownership Change on Nov. 2, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

Aspen Neuroscience SEC Filing History

Browse Aspen Neuroscience's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

Filing Date
0 Results
DateFilerForm TypeView
11/02/2026 8:46 PM
ARCH Venture Fund XIV, L.P. (2138046) Reporting
ARCH Venture Partners XIV, L.P. (2147717) Reporting
ARCH Venture Partners XIV, LLC (2148927) Reporting
Aspen Neuroscience (2124080) Issuer
BERNS PAUL L (1202769) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/02/2026 8:50 PM
ARCH Venture Fund X Overage, L.P. (1757017) Reporting
ARCH Venture Fund X, L.P. (1757011) Reporting
ARCH Venture Partners X Overage, L.P. (1768905) Reporting
ARCH Venture Partners X, L.P. (1782583) Reporting
ARCH Venture Partners X, LLC (1769012) Reporting
Aspen Neuroscience (2124080) Issuer
Burow Kristina (1569248) Reporting
CRANDELL KEITH (1219039) Reporting
GILLIS STEVEN (1229592) Reporting
NELSEN ROBERT (1219042) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/02/2026 8:03 PM
Aspen Neuroscience (2124080) Issuer
Hasnain Faheem (1352620) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/02/2026 8:05 PM
Aspen Neuroscience (2124080) Issuer
Spaventa Andrew (1859701) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/02/2026 4:25 PM
Aspen Neuroscience (2124080) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
10/30/2026 3:38 PM
Aspen Neuroscience (2124080) Filer
Form 424B4
10/29/2026 11:15 PM
Aspen Neuroscience (2124080) Filer
Form EFFECT
10/29/2026 7:29 PM
Aspen Neuroscience (2124080) Issuer
ORBIMED ADVISORS LLC (1055951) Reporting
OrbiMed Capital GP VII LLC (1760648) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 7:14 PM
Aspen Neuroscience (2124080) Issuer
Hasnain Faheem (1352620) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 7:16 PM
Aspen Neuroscience (2124080) Issuer
Spaventa Andrew (1859701) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 7:24 PM
Aspen Neuroscience (2124080) Issuer
Boerneke Jeffrey Lee (2162676) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 7:00 PM
Aspen Neuroscience (2124080) Issuer
Fisher Douglas Carl (1572355) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 7:04 PM
Aspen Neuroscience (2124080) Issuer
McDevitt Damien (1742277) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 7:05 PM
Aspen Neuroscience (2124080) Issuer
Thompson Peter A. (1357522) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 7:10 PM
Aspen Neuroscience (2124080) Issuer
Daniel Thomas O (1538894) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 7:11 PM
ARCH Venture Fund X Overage, L.P. (1757017) Reporting
ARCH Venture Fund X, L.P. (1757011) Reporting
ARCH Venture Partners X Overage, L.P. (1768905) Reporting
ARCH Venture Partners X, L.P. (1782583) Reporting
ARCH Venture Partners X, LLC (1769012) Reporting
Aspen Neuroscience (2124080) Issuer
Burow Kristina (1569248) Reporting
CRANDELL KEITH (1219039) Reporting
GILLIS STEVEN (1229592) Reporting
NELSEN ROBERT (1219042) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 6:47 PM
Aspen Neuroscience (2124080) Issuer
Johnson-Pratt Lisa (1849760) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 6:48 PM
Aspen Neuroscience (2124080) Issuer
Raineri Kim (2162455) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 6:55 PM
Aspen Neuroscience (2124080) Issuer
Meeter Dalen (1859032) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 6:57 PM
Aspen Neuroscience (2124080) Issuer
Peterson Caryn (1857256) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 6:40 PM
Aspen Neuroscience (2124080) Issuer
Perettie Cynthia Dorothy (2162497) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/29/2026 11:03 AM
Aspen Neuroscience (2124080) Filer
Form CERT
10/29/2026 5:53 AM
Aspen Neuroscience (2124080) Filer
Form 8-A12B
10/26/2026 5:54 AM
Aspen Neuroscience (2124080) Filer
Form S-1/A
10/22/2026 6:00 AM
Aspen Neuroscience (2124080) Filer
Form S-1/A
10/09/2026 3:12 PM
Aspen Neuroscience (2124080) Filer
Form S-1
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Aspen Neuroscience SEC Filings - Frequently Asked Questions

Aspen Neuroscience (ASPE) has submitted 26+ filings to the SEC since 2026. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 4 submitted on November 2, 2026. This was an insider ownership change filed by 4 - Aspen Neuroscience, Inc. (0002124080) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:ASPE are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 11/2/2026. New filings are added as they're published.
From Our Partners